4.6 Review

Antiplatelet therapy after transcatheter aortic valve implantation: a systematic review and meta-analysis

Journal

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY
Volume 60, Issue 5, Pages 1022-1029

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/ejcts/ezab250

Keywords

Aspirin; Clopidogrel; Aortic stenosis

Ask authors/readers for more resources

The meta-analysis found that double antiplatelet therapy after TAVI increased the risk of bleeding compared to single antiplatelet therapy, with no significant difference in the risk of stroke, myocardial infarction, and all-cause mortality between the two groups.
OBJECTIVES: The aim of this study was to compare antithrombotic regimens after transcatheter aortic valve implantation (TAVI) in patients without an indication for long-term anticoagulation. TAVI is a safe and effective approach for patients with symptomatic severe aortic stenosis and an intermediate-to-high surgical risk. Nevertheless, the antithrombotic regimen after procedure remains controversial. METHODS: We systematically searched PubMed, Embase and Cochrane databases for interventional studies comparing single antiplatelet therapy with double antiplatelet therapy after TAVI. A meta-analysis was carried out to compare thrombotic and bleeding events between both strategies. RESULTS: Four randomized clinical trials were included comprising a total of 1085 patients. Our meta-analysis revealed a higher odds ratio (OR) of major bleeding events (pooled OR 2.45, 95% confidence interval (CI) 1.29-4.67; P < 0.01; I-2 = 0%) and minor bleeding (pooled OR 1.73, 95% CI 1.12-2.66; P = 0.01; I-2 = 0%) for the double antiplatelet therapy group compared with the single antiplatelet therapy group. There was no difference between groups in the risk of stroke (pooled OR 1.04, 95% CI 0.58-1.86; P = 0.91; I-2 = 0%), myocardial infarction (pooled OR 2.10, 95% CI 0.75-5.84; P = 0.16, I-2 = 0%) and all-cause mortality (pooled OR 1.07, 95% CI 0.63-1.86; P = 0.08; I-2 = 0%) after TAVI. CONCLUSIONS: Our pooled analysis suggests that for patients who underwent TAVI, double antiplatelet therapy compared with single antiplatelet therapy alone increased the risk of bleeding without reducing mortality and ischaemic events.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available